Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | KMO | O15229 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 6/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | PDE5A | O76074 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20524994 | 1.00 | MAPK1 (0.47) | MAPK1SMN1; SMN2TDP1KMOKDM1A | |
| SCHEMBL29793453 | 1.00 | MAPK1 (0.47) | MAPK1SMN1; SMN2TDP1KMOKDM1A | |
| SCHEMBL24890704 | 0.87 | DGAT2 (0.44) | MAPK1SMN1; SMN2TDP1KDM1ASLC9A1 | |
| SCHEMBL17003109 | 0.87 | DGAT2 (0.44) | MAPK1SMN1; SMN2TDP1KDM1ASLC9A1 | |
| SCHEMBL17003112 | 0.87 | DGAT2 (0.44) | MAPK1SMN1; SMN2TDP1KDM1ASLC9A1 | |
| SCHEMBL15977388 | 0.84 | MAPK1 (0.55) | MAPK1SMN1; SMN2TDP1KDM1AMAOB | |
| SCHEMBL15977397 | 0.84 | MAPK1 (0.55) | MAPK1SMN1; SMN2TDP1KDM1AMAOB | |
| SCHEMBL15977398 | 0.84 | MAPK1 (0.55) | MAPK1SMN1; SMN2TDP1KDM1AMAOB | |
| SCHEMBL20524971 | 0.83 | MAPK1 (0.45) | MAPK1SMN1; SMN2TDP1KDM1AMAOB | |
| SCHEMBL20524969 | 0.83 | MAPK1 (0.45) | MAPK1SMN1; SMN2TDP1KDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018012-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230130470-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | ALCON INC. (CH) | 2023-04-27 | — | — | US | disclosed |
| CN-114790186-A | Fused ring compound as EP4 antagonist and preparation method and application thereof | 武汉人福创新药物研发中心有限公司 | 2022-07-26 | — | — | CN | disclosed |
| US-11312700-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20210002253-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | ALCON INC. (CH) | 2021-01-07 | — | — | US | disclosed |
| US-10858339-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2020-12-08 | — | — | US | disclosed |
| EP-3609871-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | Aerie Pharmaceuticals, Inc. (US) | 2020-02-19 | — | — | EP | disclosed |
| US-20180327381-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | ALCON INC. (CH) | 2018-11-15 | — | — | US | disclosed |
| WO-2018183911-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | AERIE PHARMACEUTICALS, INC. (US) | 2018-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210002253-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | UACA, HRAS, MYLK | MAPK1 281/4885SMN1; SMN2 4577/4885TDP1 710/4885 |
| US-12018012-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | UACA, HRAS, MYLK | MAPK1 281/4885SMN1; SMN2 4577/4885TDP1 710/4885 |
| US-20180327381-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | UACA, HRAS, MYLK | MAPK1 281/4885SMN1; SMN2 4577/4885TDP1 710/4885 |
| US-11312700-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | UACA, HRAS, MYLK | MAPK1 281/4885SMN1; SMN2 4577/4885TDP1 710/4885 |
| US-10858339-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | UACA, HRAS, MYLK | MAPK1 281/4885SMN1; SMN2 4577/4885TDP1 710/4885 |
| US-20230130470-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | UACA, HRAS, MYLK | MAPK1 281/4885SMN1; SMN2 4577/4885TDP1 710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.